New hope for kids: drug trio aims to stop transplant rejection
NCT ID NCT07350057
First seen Jan 28, 2026 · Last updated May 13, 2026 · Updated 18 times
Summary
This study tests whether adding an experimental drug (VIC-1911) to two standard medicines can prevent graft-versus-host disease (GVHD) in children aged 8–18 who receive a half-matched stem cell transplant for blood cancers. The trial has two parts: first, checking safety and the right dose; second, testing how well the combination works. Only 9 children will take part in this early-phase study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD (ACUTE OR CHRONIC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.